Anne-Marie Schjerning Olsen

Medicine & Life Sciences

1. Cohort Studies 100%
2. Anti-Inflammatory Agents 92%
3. Myocardial Infarction 92%
4. Atrial Fibrillation 81%
5. Pharmaceutical Preparations 52%
6. Heart Failure 28%
7. Hemorrhage 25%
8. Thyroxine 25%
9. Mortality 25%
10. Confidence Intervals 24%
11. Stroke 23%
12. Clopidogrel 21%
13. Catheter Ablation 19%
14. Thromboembolism 18%
15. Denmark 18%
16. Hypothyroidism 18%
17. Drug Therapy 17%
18. Therapeutics 16%
19. Safety 16%
20. Ibuprofen 15%
21. Naproxen 15%
22. Diclofenac 14%
23. Incidence 13%
24. Proprotein Convertase 9 12%
25. Cardiovascular Diseases 12%
26. Hydroxymethylglutaryl-CoA Reductase Inhibitors 11%
27. Duration of Therapy 11%
28. Celecoxib 11%
29. Comorbidity 11%
30. Dabigatran 11%
31. Out-of-Hospital Cardiac Arrest 10%
32. Registries 10%
33. Electric Countershock 10%
34. Thyroid Diseases 10%
35. Hypertrophic Cardiomyopathy 9%
36. Proton Pump Inhibitors 9%
37. Aspirin 9%
38. Peripheral Arterial Disease 9%
39. rofecoxib 9%
40. Syncope 9%
41. Non-Steroidal Anti-Inflammatory Agents 9%
42. Venous Thromboembolism 9%
43. Hyperthyroidism 8%
44. Anticoagulants 8%
45. Warfarin 8%
46. Thyroid Gland 8%
47. International Classification of Diseases 8%
48. Coronary Disease 8%
49. Thrombosis 8%
50. Coronary Angiography 8%